Millennium Management’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

Millennium Management’s Portfolio BXRX Stock Details BXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-648	Closed	-$6K	–	7780
2022 Q3	$6K	Buy	+648	New	+$15.1K	﹤0.01%	6804
2022 Q1	–	Sell	-53	Closed	-$16K	–	8074
2021 Q4	$16K	Sell	53 -181	-77%	-$113K	﹤0.01%	6618
2021 Q3	$184K	Buy	234 +192	+457%	+$167K	﹤0.01%	6163
2021 Q2	$45K	Buy	42 +28	+200%	+$36.6K	﹤0.01%	6379
2021 Q1	$26K	Hold	14	–	–	﹤0.01%	5812
2020 Q4	$19K	Sell	14 -13	-48%	-$26.6K	﹤0.01%	5134
2020 Q3	$105	Sell	27 -170	-86%	-$769K	﹤0.01%	4211
2020 Q2	$1.14M	Buy	197 +164	+497%	+$787K	﹤0.01%	2919
2020 Q1	$115K	Sell	33 -79	-71%	-$746K	﹤0.01%	3528
2019 Q4	$1.08M	Buy	+112	New	+$956K	﹤0.01%	2967

Other funds holding BXRX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sittner & Nelson Eugene, Oregon $274M AUM 22.46% 1-Year Est. Return

Millennium Management's BXRX Position: Q4 2022 in Review

Millennium Management sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q4 2022, closing a stake of 648 shares — an estimated $6K sold.

Millennium Management first reported a position in BXRX in Q4 2019 and held it in 10 quarters. The position peaked at $1.14M in Q2 2020. 10 funds tracked by Wall St. Rank hold BXRX as of Q4 2022.

Millennium Management reported no remaining Baudax Bio, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Millennium Management sold 648 Baudax Bio, Inc. Common Stock shares in Q4 2022, an estimated $6K.
Millennium Management first reported a position in Baudax Bio, Inc. Common Stock in Q4 2019 and held it in 10 quarters.
Millennium Management's Baudax Bio, Inc. Common Stock position peaked at $1.14M in Q2 2020.
10 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q4 2022.

Based on Millennium Management's 13F filing for Q4 2022, filed 14 Feb 2023.